ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack FDA Decision: Agios Pharmaceuticals (AGIO)

The Phase 3 date for ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack by Agios Pharmaceuticals (AGIO) is scheduled for December 14, 2026. This is the target date for the FDA to make a decision on this application.

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack is being developed by Agios Pharmaceuticals for the treatment of its target indication. It is currently in Phase 3 clinical trials.

If ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack receives FDA approval, Agios Pharmaceuticals (AGIO) would be able to market the drug in the United States for its target indication. This typically leads to significant stock price movement for biotech companies. Investors should monitor the Phase 3 date closely.

Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for AGIO on DilutionWatch at dilutionwatch.com/stock/AGIO.html.

You can view the full BiotechSigns company profile for Agios Pharmaceuticals (AGIO) at biotechsign.com/app/company/AGIO, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.